Roth Capital Releases a Buy Rating on Arch Therapeutics Inc

By Jason Carr

In a report released yesterday, Michael Higgins from Roth Capital reiterated a Buy rating on Arch Therapeutics Inc (Other OTC: ARTH), with a price target of $3. The company’s shares opened today at $0.60.

According to, Higgins is ranked 0 out of 5 stars with an average return of -13.1% and a 28.4% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Sucampo Pharmaceuticals, Juniper Pharmaceuticals, and Zynerba Pharmaceuticals.

Arch Therapeutics Inc has an analyst consensus of Moderate Buy.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arch Therapeutics, Inc. is a biotechnology company, which engages in developing an innovative, elegant, and superior approach to the rapid cessation of bleeding and control of fluid leakage during surgery and trauma care. Its product candidate surgical hemostatic device is designed to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.